PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy

Cervical cancer is largely driven by human papillomavirus (HPV) infection, yet clinically actionable molecular subtypes and effective targeted therapies remain limited. Here, we define biologically and clinically relevant subtypes and evaluate targeted therapeutic strategies. Analysis of public data...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hong Lou, David Langan, Nick Syracuse, Elisabeth A. Murphy, Sojung Kim, Emma Robinson, Nicole M. Rossi, Yi Xie, Sonam Tulsyan, Tawnjerae Joe, Isabel Rodriguez, Nina Rao, Matthew R. Oberley, Mathias Oelke, Michael Dean
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-06-01
coleção:	Neoplasia: An International Journal for Oncology Research
Assuntos:	Cervical cancer, Immunotherapy, Immune checkpoint inhibitor, Major histocompatibility complex MHC, Virology, Real-world data, Clinical outcomes
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558626000345
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!